BioRestorative Therapies Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $357.9K-10.8% YoYTTM through 31 Mar 2026
Net Income -$11.1MTTM through 31 Mar 2026
Free Cash Flow -$12MTTM through 31 Mar 2026
Margins
| Current | |
|---|---|
| Gross Margin | 93.4% |
| Operating Margin | -4,350.1% |
| Net Margin | -3,089.6% |
Balance Sheet Health
Debt / Equity0.00x
Current Ratio0.84x
Net Debt-$3Mnet cash position
Cash & Equivalents$3.1M
Quality Metrics
Altman Z-Score-60.08
Piotroski F-Score2 / 9
FCF Margin-3,356.2%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $359.7K
Diluted EPS-$1.06TTMFY2025: $-1.58
Dividend
No dividend
Capital Allocation
Capex Intensity53.9%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Royalty | $59.7K | -40.9% | View detailsRoyalty revenue has declined due to fewer disc procedures. |
| Cosmetic Product Sales | $300K | 0.0% | View detailsThe company launched its BioX cosmetic line to expand aesthetic product sales. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.